Quick Answer
Senti Biosciences Holdings, Inc. reported Operating Income Loss of -$68.78 million for the year ending 2025.
- Senti Biosciences Holdings, Inc. showed a decrease of -12.7% in Operating Income Loss from 2024 to 2025.
- This data is from Senti Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Senti Biosciences Holdings, Inc.'s Operating Income Loss has declined by 70.1%.
- Historical annual values: Fiscal year 2025: -$68.78 million | Fiscal year 2024: -$61.04 million | Fiscal year 2023: -$92.73 million | Fiscal year 2022: -$62.08 million | Fiscal year 2021: -$40.45 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: